Back to top
more

Catalent (CTLT)

(Real Time Quote from BATS)

$60.00 USD

60.00
715,782

+0.05 (0.08%)

Updated Nov 7, 2024 01:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session

by Zacks Equity Research

Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Ironwood to End IW-3718 Development After Study Failure

by Zacks Equity Research

Ironwood's (IRWD) pipeline candidate, IW-3718, fails to meet primary endpoint in a phase III study evaluating it in patients with refractory GERD.

Endo (ENDP) Surges: Stock Moves 8.4% Higher

by Zacks Equity Research

Endo (ENDP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Revolution Medicines (RVMD) Looks Good: Stock Adds 6.9% in Session

by Zacks Equity Research

Revolution Medicines (RVMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Spectrum Pharmaceuticals (SPPI) Jumps: Stock Rises 7%

by Zacks Equity Research

Spectrum Pharmaceuticals (SPPI) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

Vaxart (VXRT) Surges: Stock Moves 8.1% Higher

by Zacks Equity Research

Vaxart (VXRT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Champions Oncology (CSBR) Catches Eye: Stock Jumps 9.2%

by Zacks Equity Research

Champions Oncology (CSBR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Marinus Pharmaceuticals (MRNS) Soars: Stock Adds 5.5% in Session

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Etsy, Generac, Catalent, Fortune Brands Home & Security and Wayfair

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Etsy, Generac, Catalent, Fortune Brands Home & Security and Wayfair

Sage Therapeutics (SAGE) in Focus: Stock Moves 5.1% Higher

by Zacks Equity Research

Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Nalak Das headshot

6 Top Stocks That Turned Large Cap From Mid Cap Amid Pandemic

by Nalak Das

In the due course of the S&P 400 Index's fabulous performance in the past five months, several mid-cap stocks have become large caps. We have selected six of these that carry a favorable Zacks Rank.

Tirthankar Chakraborty headshot

New Strong Buy Stocks For September 11th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Exelixis Inks a Couple of Deals to Develop Novel ADCs for Cancer

by Zacks Equity Research

Exelixis (EXEL) signs a collaboration agreement with private biotech NBE-Therapeutics for developing novel antibody-drug conjugates (ADCS) to address cancer. It also inks a similar deal with Catalent.

Merck Announces Detailed Data on Late-Stage Cough Candidate

by Zacks Equity Research

Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.

Radius Completes Enrollment in Phase III Osteoporosis Study

by Zacks Equity Research

Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Is Catalent (CTLT) a Great Growth Stock?

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

Is Catalent (CTLT) a Great Growth Stock?

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

David Borun headshot

High-Flying Equities Stumble, but Remain Near All-Time Highs

by David Borun

Technology stocks slip modestly as investors reassess valuations after an historic rally off March lows.

Company News for Sep1, 2020

by Zacks Equity Research

Companies In The News Are: CTLT, TSLA, AIMT, AMZN.

Catalent (CTLT) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 0.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y

by Zacks Equity Research

Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.

Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors focus is likely to be on the progress of its pipeline candidates, especially coronavirus vaccine candidate, on the second-quarter earrings call.

    Moderna Collaborates to Support Coronavirus Vaccine Supply

    by Zacks Equity Research

    Moderna (MRNA) signs manufacturing deal with Europe-based pharma company, Rovi, to support supply of its coronavirus vaccine in ex-US markets.

      Moderna Completes Enrollment in Phase II Coronavirus Study

      by Zacks Equity Research

      Moderna (MRNA) is progressing well with its coronavirus vaccine development. It completes enrollment in a phase II study and finalizes phase III study protocol.